A survey has found that cost is the biggest barrier to accessing GLP-1, with a significant percentage of users reporting that cost influenced their treatment decisions. The survey results show that around 68-70% of GLP-1 users consider cost a key factor in their treatment choices. Meanwhile, a subscription-based program for a GLP-1 related treatment has been launched, potentially addressing cost concerns.